Poor-prognosis high-grade gliomas: evolving an evidence-based standard of care (Q34826601)

4 August 2017

1 reference

title

Poor-prognosis high-grade gliomas: evolving an evidence-based standard of care (English)

1 reference

4 August 2017

1

Tejpal Gupta

1 reference

4 August 2017

Rajiv Sarin

2

1 reference

4 August 2017

publication date

1 September 2002

1 reference

Lancet Oncology Commission

4 August 2017

published in

1 reference

4 August 2017

volume

3

1 reference

4 August 2017

issue

9

1 reference

4 August 2017

page(s)

557-564

1 reference

4 August 2017

cites work

Cancer statistics, 2000.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900853-7

7 January 2021

Prognostic factors for high-grade malignant glioma: development of a prognostic index. A Report of the Medical Research Council Brain Tumour Working Party

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900853-7

7 January 2021

Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900853-7

7 January 2021

The basis for current treatment recommendations for malignant gliomas

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900853-7

7 January 2021

American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900853-7

7 January 2021

Glioblastoma multiforme and anaplastic astrocytoma. Pathologic criteria and prognostic implications

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900853-7

7 January 2021

Univariate and multivariate statistical analysis of high-grade gliomas: the relationship of radiation dose and other prognostic factors.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900853-7

7 January 2021

Survival and prognosis of patients with astrocytoma with atypical or anaplastic features.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900853-7

7 January 2021

Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas. A joint Radiation Therapy Oncology Group and Eastern Cooperative Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900853-7

7 January 2021

The limited value of cytoreductive surgery in elderly patients with malignant gliomas

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900853-7

7 January 2021

Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900853-7

7 January 2021

Combined modality therapy of operated astrocytomas grade III and IV. Confirmation of the value of postoperative irradiation and lack of potentiation of bleomycin on survival time: a prospective multicenter trial of the Scandinavian Glioblastoma Stud

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900853-7

7 January 2021

Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900853-7

7 January 2021

Outcome in elderly patients undergoing definitive surgery and radiation therapy for supratentorial glioblastoma multiforme at a tertiary care institution.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900853-7

7 January 2021

Management of patients aged over 60 years with supratentorial glioma: lessons from an audit.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900853-7

7 January 2021

An analysis of dose-effect relationship in the radiotherapy of malignant gliomas

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900853-7

7 January 2021

A Medical Research Council trial of two radiotherapy doses in the treatment of grades 3 and 4 astrocytoma. The Medical Research Council Brain Tumour Working Party

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900853-7

7 January 2021

Assumptions in the radiotherapy of glioblastoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900853-7

7 January 2021

Malignant glioma: patterns of failure following individually tailored limited volume irradiation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900853-7

7 January 2021

Randomized trial of three chemotherapy regimens and two radiotherapy regimens and two radiotherapy regimens in postoperative treatment of malignant glioma. Brain Tumor Cooperative Group Trial 8001.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900853-7

7 January 2021

Radiotherapy of glioblastoma multiforme

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900853-7

7 January 2021

Postoperative hypofractionated radiotherapy versus conventionally fractionated radiotherapy in malignant gliomas. A preliminary report on a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900853-7

7 January 2021

Glioblastoma in the older patient: how long a course of radiotherapy is necessary?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900853-7

7 January 2021

A prospective study of short-course radiotherapy in poor prognosis glioblastoma multiforme.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900853-7

7 January 2021

Hypofractionated radiotherapy as palliative treatment in poor prognosis patients with high grade glioma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900853-7

7 January 2021

Hypofractionated radiation therapy in patients with glioblastoma multiforme: results of treatment and impact of prognostic factors.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900853-7

7 January 2021

Short course radiotherapy is an appropriate option for most malignant glioma patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900853-7

7 January 2021

A prospective study of short course radiotherapy in elderly patients with malignant glioma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900853-7

7 January 2021

A short fractionation radiotherapy treatment for poor prognosis patients with high grade glioma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900853-7

7 January 2021

Short-course radiotherapy in elderly and frail patients with glioblastoma multiforme. A phase II study.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900853-7

7 January 2021

Hypofractionation in glioblastoma multiforme.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900853-7

7 January 2021

The effect of waiting for radiotherapy for grade III/IV gliomas.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900853-7

7 January 2021

Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900853-7

7 January 2021

Randomized trial of procarbazine, lomustine, and vincristine in the adjuvant treatment of high-grade astrocytoma: a Medical Research Council trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900853-7

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900853-7

7 January 2021

A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900853-7

7 January 2021

DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900853-7

7 January 2021

Dose-effect relationship of dexamethasone on Karnofsky performance in metastatic brain tumors: a randomized study of doses of 4, 8, and 16 mg per day.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900853-7

7 January 2021

Final results of the Royal College of Radiologists' trial comparing two different radiotherapy schedules in the treatment of cerebral metastases

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900853-7

7 January 2021

Response and progression in recurrent malignant glioma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900853-7

7 January 2021

Verbally administered Barthel Index as functional assessment in brain tumour patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900853-7

7 January 2021

Quality of life as an endpoint in EORTC clinical trials. European Organization for Research and Treatment for Cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900853-7

7 January 2021

The development and psychometric validation of a brain cancer quality-of-life questionnaire for use in combination with general cancer-specific questionnaires

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900853-7

7 January 2021

The Functional Assessment of Cancer Therapy (FACT) scale. Development of a brain subscale and revalidation of the general version (FACT-G) in patients with primary brain tumors.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900853-7

7 January 2021

10.1016/S1470-2045(02)00853-7

Identifiers

DOI

1 reference

4 August 2017

1 reference